Ginkgo bioworks reports third quarter 2023 financial results

Ginkgo added 21 new cell programs to the foundry platform in q3 2023 entered into strategic cloud and ai partnership with google cloud; first milestone recently achieved signed new multi-target rna drug discovery collaboration with pfizer in which ginkgo is eligible to receive research fees and development and commercial milestone payments of up to $331 million ginkgo ended q3 2023 with over $1.0 billion in cash and cash equivalents, maintaining a multi-year runway as ginkgo continues to drive towards profitability boston , nov. 8, 2023 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended september 30, 2023. the update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking